Cargando…

The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective

Neurofibromatosis type 1 (NF1) can affect multiple systems in the body. An under recognised phenotype is one of muscle weakness. Clinical studies using dynamometry and jumping mechanography have demonstrated that children with NF1 are more likely to have reduced muscle force and power. Many children...

Descripción completa

Detalles Bibliográficos
Autores principales: Chinoy, Amish, Vassallo, Grace R., Wright, Emma Burkitt, Eelloo, Judith, West, Siobhan, Hupton, Eileen, Galloway, Paula, Pilkington, Amy, Padidela, Raja, Mughal, M. Zulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Musculoskeletal and Neuronal Interactions 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919663/
https://www.ncbi.nlm.nih.gov/pubmed/35234161
_version_ 1784668979778813952
author Chinoy, Amish
Vassallo, Grace R.
Wright, Emma Burkitt
Eelloo, Judith
West, Siobhan
Hupton, Eileen
Galloway, Paula
Pilkington, Amy
Padidela, Raja
Mughal, M. Zulf
author_facet Chinoy, Amish
Vassallo, Grace R.
Wright, Emma Burkitt
Eelloo, Judith
West, Siobhan
Hupton, Eileen
Galloway, Paula
Pilkington, Amy
Padidela, Raja
Mughal, M. Zulf
author_sort Chinoy, Amish
collection PubMed
description Neurofibromatosis type 1 (NF1) can affect multiple systems in the body. An under recognised phenotype is one of muscle weakness. Clinical studies using dynamometry and jumping mechanography have demonstrated that children with NF1 are more likely to have reduced muscle force and power. Many children with NF1 are unable to undertake physical activities to the same level as their peers, and report leg pains on physical activity and aching hands on writing. Children and adolescents with NF1 reporting symptoms of muscle weakness should have a focused assessment to exclude alternative causes of muscle weakness. Assessments of muscle strength and fine motor skills by physiotherapists and occupational therapists can provide objective evidence of muscle function and deficits, allowing supporting systems in education and at home to be implemented. In the absence of an evidence base for management of NF1-related muscle weakness, we recommend muscle-strengthening exercises and generic strategies for pain and fatigue management. Currently, trials are underway involving whole-body vibration therapy and carnitine supplementation as potential future management options.
format Online
Article
Text
id pubmed-8919663
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher International Society of Musculoskeletal and Neuronal Interactions
record_format MEDLINE/PubMed
spelling pubmed-89196632022-04-14 The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective Chinoy, Amish Vassallo, Grace R. Wright, Emma Burkitt Eelloo, Judith West, Siobhan Hupton, Eileen Galloway, Paula Pilkington, Amy Padidela, Raja Mughal, M. Zulf J Musculoskelet Neuronal Interact Review Article Neurofibromatosis type 1 (NF1) can affect multiple systems in the body. An under recognised phenotype is one of muscle weakness. Clinical studies using dynamometry and jumping mechanography have demonstrated that children with NF1 are more likely to have reduced muscle force and power. Many children with NF1 are unable to undertake physical activities to the same level as their peers, and report leg pains on physical activity and aching hands on writing. Children and adolescents with NF1 reporting symptoms of muscle weakness should have a focused assessment to exclude alternative causes of muscle weakness. Assessments of muscle strength and fine motor skills by physiotherapists and occupational therapists can provide objective evidence of muscle function and deficits, allowing supporting systems in education and at home to be implemented. In the absence of an evidence base for management of NF1-related muscle weakness, we recommend muscle-strengthening exercises and generic strategies for pain and fatigue management. Currently, trials are underway involving whole-body vibration therapy and carnitine supplementation as potential future management options. International Society of Musculoskeletal and Neuronal Interactions 2022 /pmc/articles/PMC8919663/ /pubmed/35234161 Text en Copyright: © Journal of Musculoskeletal and Neuronal Interactions https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Chinoy, Amish
Vassallo, Grace R.
Wright, Emma Burkitt
Eelloo, Judith
West, Siobhan
Hupton, Eileen
Galloway, Paula
Pilkington, Amy
Padidela, Raja
Mughal, M. Zulf
The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective
title The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective
title_full The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective
title_fullStr The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective
title_full_unstemmed The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective
title_short The skeletal muscle phenotype of children with Neurofibromatosis Type 1 – A clinical perspective
title_sort skeletal muscle phenotype of children with neurofibromatosis type 1 – a clinical perspective
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919663/
https://www.ncbi.nlm.nih.gov/pubmed/35234161
work_keys_str_mv AT chinoyamish theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT vassallogracer theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT wrightemmaburkitt theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT eelloojudith theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT westsiobhan theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT huptoneileen theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT gallowaypaula theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT pilkingtonamy theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT padidelaraja theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT mughalmzulf theskeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT chinoyamish skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT vassallogracer skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT wrightemmaburkitt skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT eelloojudith skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT westsiobhan skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT huptoneileen skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT gallowaypaula skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT pilkingtonamy skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT padidelaraja skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective
AT mughalmzulf skeletalmusclephenotypeofchildrenwithneurofibromatosistype1aclinicalperspective